Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.

Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N.

JAMA Oncol. 2020 Feb 13:e196496. doi: 10.1001/jamaoncol.2019.6496. [Epub ahead of print]

PMID:
32053149
2.

Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.

Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, Leverson G, Woo K, Sonn GA, Klein EA, Fumo M, Huang W, Jarrard DF.

Clin Epigenetics. 2019 Nov 28;11(1):168. doi: 10.1186/s13148-019-0771-5.

3.

Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery.

Shapiro DD, Wells SA, Best SL, Hedican SP, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT Jr, Jarrard DF, Richards KA, Downs TM, Allen GO, Nakada SY, Abel EJ.

Urology. 2020 Jan;135:88-94. doi: 10.1016/j.urology.2019.09.024. Epub 2019 Oct 1.

PMID:
31585198
4.

Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides.

Rutkowski DR, Wells SA, Johnson B, Huang W, Jarrard DF, Lang JM, Cho S, Roldán-Alzate A.

Am J Clin Exp Urol. 2019 Aug 15;7(4):215-222. eCollection 2019.

5.

Reconfigurable open microfluidics for studying the spatiotemporal dynamics of paracrine signalling.

Yu J, Berthier E, Craig A, de Groot TE, Sparks S, Ingram PN, Jarrard DF, Huang W, Beebe DJ, Theberge AB.

Nat Biomed Eng. 2019 Oct;3(10):830-841. doi: 10.1038/s41551-019-0421-4. Epub 2019 Aug 19.

PMID:
31427781
6.

Impact of bilateral biopsy-detected prostate cancer on an active surveillance population.

Wang JH, Sierra P, Richards KA, Abel EJ, Allen GO, Downs TM, Jarrard DF.

BMC Urol. 2019 Apr 23;19(1):26. doi: 10.1186/s12894-019-0452-x.

7.

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier.

Etheridge T, Damodaran S, Schultz A, Richards KA, Gawdzik J, Yang B, Cryns V, Jarrard DF.

Asian J Urol. 2019 Jan;6(1):57-64. doi: 10.1016/j.ajur.2018.09.001. Epub 2018 Sep 15. Review.

8.

Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.

Damodaran S, Lang JM, Jarrard DF.

J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. Review.

PMID:
30747897
9.

The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study.

Anderson-Carter I, Posielski N, Liou JI, Khemees TA, Downs TM, Abel EJ, Jarrard DF, Richards KA.

Urol Oncol. 2019 Feb;37(2):130-137. doi: 10.1016/j.urolonc.2018.11.017. Epub 2018 Dec 7.

10.

Semen AMACR protein as a novel method for detecting prostate cancer.

Etheridge T, Straus J, Ritter MA, Jarrard DF, Huang W.

Urol Oncol. 2018 Dec;36(12):532.e1-532.e7. doi: 10.1016/j.urolonc.2018.09.010. Epub 2018 Oct 15.

PMID:
30337219
11.

The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.

Etheridge T, Liou JI, Downs TM, Abel EJ, Jarrard DF, Richards KA.

J Urol. 2019 Apr;201(4):742-750. doi: 10.1016/j.juro.2018.10.005.

PMID:
30321553
12.

Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.

Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS.

J Urol. 2018 Dec;200(6):1264-1272. doi: 10.1016/j.juro.2018.07.090. Epub 2018 Aug 4.

PMID:
30086276
13.

The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.

Etheridge T, Liou J, Downs TM, Abel EJ, Richards KA, Jarrard DF.

Am J Clin Exp Urol. 2018 Jun 15;6(3):123-132. eCollection 2018.

14.

HyPR-MS for Multiplexed Discovery of MALAT1, NEAT1, and NORAD lncRNA Protein Interactomes.

Spiniello M, Knoener RA, Steinbrink MI, Yang B, Cesnik AJ, Buxton KE, Scalf M, Jarrard DF, Smith LM.

J Proteome Res. 2018 Sep 7;17(9):3022-3038. doi: 10.1021/acs.jproteome.8b00189. Epub 2018 Jul 31.

15.

Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.

Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF.

J Urol. 2018 Dec;200(6):1256-1263. doi: 10.1016/j.juro.2018.06.031. Epub 2018 Jun 22.

PMID:
29940252
16.

Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort.

Maciolek KA, Best SL, Lopez V, Posielski N, Knoedler M, Bushman WA, Jarrard DF, Downs TM, Abel EJ, Richards KA.

Urol Oncol. 2018 Aug;36(8):363.e13-363.e20. doi: 10.1016/j.urolonc.2018.05.009. Epub 2018 Jun 7.

PMID:
29887242
17.

Long Noncoding RNAs AC009014.3 and Newly Discovered XPLAID Differentiate Aggressive and Indolent Prostate Cancers.

Cesnik AJ, Yang B, Truong A, Etheridge T, Spiniello M, Steinbrink MI, Shortreed MR, Frey BL, Jarrard DF, Smith LM.

Transl Oncol. 2018 Jun;11(3):808-814. doi: 10.1016/j.tranon.2018.04.002. Epub 2018 May 1.

18.

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ.

J Clin Oncol. 2018 Apr 10;36(11):1088-1095. doi: 10.1200/JCO.2017.75.3335. Epub 2018 Mar 9.

19.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ.

J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31.

20.

Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment.

Johnson BP, Vitek RA, Geiger PG, Huang W, Jarrard DF, Lang JM, Beebe DJ.

Biotechniques. 2018 Jan 1;64(1):13-19. doi: 10.2144/000114626.

21.

Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study.

Richards KA, Ruiz VL, Murphy DR, Downs TM, Abel EJ, Jarrard DF, Singh H.

Urol Oncol. 2018 Mar;36(3):88.e19-88.e25. doi: 10.1016/j.urolonc.2017.11.004. Epub 2017 Nov 21.

PMID:
29169843
22.

Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?

Damodaran S, Kyriakopoulos CE, Jarrard DF.

Urol Clin North Am. 2017 Nov;44(4):611-621. doi: 10.1016/j.ucl.2017.07.008. Review.

23.

Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.

Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, Jarrard DF, Denu JM.

ACS Chem Biol. 2017 Nov 17;12(11):2804-2814. doi: 10.1021/acschembio.6b01035. Epub 2017 Oct 11.

24.

Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials.

Maciolek KA, Jarrard DF, Abel EJ, Best SL.

Urology. 2017 Nov;109:101-106. doi: 10.1016/j.urology.2017.07.037. Epub 2017 Aug 2.

PMID:
28780302
25.

Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.

Damaschke NA, Yang B, Bhusari S, Avilla M, Zhong W, Blute ML Jr, Huang W, Jarrard DF.

Cancer Res. 2017 Oct 1;77(19):5236-5247. doi: 10.1158/0008-5472.CAN-16-3089. Epub 2017 Aug 3.

26.

Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.

Wang JH, Downs TM, Jason Abel E, Richards KA, Jarrard DF.

Curr Urol Rep. 2017 Jul;18(7):48. doi: 10.1007/s11934-017-0702-y. Review.

PMID:
28589399
27.

Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences.

Tazeh NN, Canter DJ, Damodaran S, Rushmer T, Richards KA, Abel EJ, Jarrard DF, Downs TM.

Bladder Cancer. 2017 Apr 27;3(2):89-94. doi: 10.3233/BLC-160085.

28.

Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.

Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM.

BJU Int. 2017 Sep;120(3):387-393. doi: 10.1111/bju.13904. Epub 2017 Jun 23.

29.

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.

Blute ML Jr, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF.

PLoS One. 2017 Feb 24;12(2):e0172048. doi: 10.1371/journal.pone.0172048. eCollection 2017.

30.

Multi-quadrant biopsy technique improves diagnostic ability in large heterogeneous renal masses. Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz T.J Urol. 2015 Oct;194(4):886-91. [Epub 2015 Mar 30]. doi: 10.1016/j.juro.2015.03.106.

Jay R, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz T.

Urol Oncol. 2017 Mar;35(3):119. doi: 10.1016/j.urolonc.2016.12.025. Epub 2017 Feb 1.

PMID:
28159492
31.

Inducible expression of cancer-testis antigens in human prostate cancer.

Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM.

Oncotarget. 2016 Dec 20;7(51):84359-84374. doi: 10.18632/oncotarget.12711.

32.

Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis.

Blute ML Jr, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ.

Urology. 2017 Feb;100:139-144. doi: 10.1016/j.urology.2016.09.016. Epub 2016 Sep 22.

PMID:
27667156
33.

A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.

Blute ML Jr, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF.

World J Urol. 2017 May;35(5):729-735. doi: 10.1007/s00345-016-1933-0. Epub 2016 Sep 15.

PMID:
27631325
34.

A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery.

Grimes MD, Blute ML Jr, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ.

Urology. 2016 Oct;96:93-98. doi: 10.1016/j.urology.2016.06.018. Epub 2016 Jun 23.

35.

Prostate cancer: The applicability of textural analysis of MRI for grading.

Kelcz F, Jarrard DF.

Nat Rev Urol. 2016 Apr;13(4):185-6. doi: 10.1038/nrurol.2016.33. Epub 2016 Feb 16. No abstract available.

PMID:
26878802
36.

The New Age of Molecular Taxonomy Approaches.

Jarrard DF, Huang W.

Eur Urol. 2016 Apr;69(4):561-562. doi: 10.1016/j.eururo.2015.11.011. Epub 2015 Nov 26. No abstract available.

PMID:
26626616
37.

Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer.

Blute ML Jr, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ.

BJU Int. 2016 Sep;118(3):399-407. doi: 10.1111/bju.13381. Epub 2015 Dec 22.

38.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS.

N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.

39.

Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.

Blute ML Jr, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM.

J Urol. 2015 Nov;194(5):1214-9. doi: 10.1016/j.juro.2015.05.104. Epub 2015 Jul 11.

PMID:
26173101
40.

Addressing the need for repeat prostate biopsy: new technology and approaches.

Blute ML Jr, Abel EJ, Downs TM, Kelcz F, Jarrard DF.

Nat Rev Urol. 2015 Aug;12(8):435-44. doi: 10.1038/nrurol.2015.159. Epub 2015 Jul 14. Review.

PMID:
26171803
41.

Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses.

Abel EJ, Heckman JE, Hinshaw L, Best S, Lubner M, Jarrard DF, Downs TM, Nakada SY, Lee FT Jr, Huang W, Ziemlewicz T.

J Urol. 2015 Oct;194(4):886-91. doi: 10.1016/j.juro.2015.03.106. Epub 2015 Mar 30.

PMID:
25837535
42.

Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer.

Damaschke NA, Yang B, Blute ML Jr, Lin CP, Huang W, Jarrard DF.

Neoplasia. 2014 Dec;16(12):1018-27. doi: 10.1016/j.neo.2014.10.003.

43.

Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development.

Keil KP, Abler LL, Laporta J, Altmann HM, Yang B, Jarrard DF, Hernandez LL, Vezina CM.

Dev Biol. 2014 Dec 15;396(2):237-45. doi: 10.1016/j.ydbio.2014.10.006. Epub 2014 Oct 23.

44.

The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.

Blute ML Jr, Damaschke NA, Jarrard DF.

Curr Opin Urol. 2015 Jan;25(1):83-8. doi: 10.1097/MOU.0000000000000132. Review.

45.

Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer.

Jarrard DF, Blute ML Jr, Ritter MA.

J Clin Oncol. 2014 Dec 10;32(35):3926-9. doi: 10.1200/JCO.2014.57.8302. Epub 2014 Oct 20. No abstract available.

PMID:
25332250
46.

Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality?

Abel EJ, Linder BJ, Bauman TM, Bauer RM, Thompson RH, Thapa P, Devon ON, Tarrell RF, Frank I, Jarrard DF, Downs TM, Boorjian SA.

Eur Urol. 2014 Dec;66(6):1139-47. doi: 10.1016/j.eururo.2014.08.051. Epub 2014 Sep 4.

PMID:
25194909
47.

Surgical operative time increases the risk of deep venous thrombosis and pulmonary embolism in robotic prostatectomy.

Abel EJ, Wong K, Sado M, Leverson GE, Patel SR, Downs TM, Jarrard DF.

JSLS. 2014 Apr-Jun;18(2):282-7. doi: 10.4293/108680813X13693422518551.

48.

Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression.

Abel EJ, Bauman TM, Weiker M, Shi F, Downs TM, Jarrard DF, Huang W.

Hum Pathol. 2014 May;45(5):1092-9. doi: 10.1016/j.humpath.2014.01.008. Epub 2014 Jan 28.

49.

A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation.

Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S, Jarrard DF.

PLoS One. 2014 Feb 18;9(2):e88052. doi: 10.1371/journal.pone.0088052. eCollection 2014.

50.

Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.

Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF.

Cancer. 2013 Nov 15;119(22):3992-4002. doi: 10.1002/cncr.28303. Epub 2013 Sep 4.

Supplemental Content

Loading ...
Support Center